| Assessing atropisomer axial chirality in drug discovery and development SR LaPlante, LD Fader, KR Fandrick, DR Fandrick, O Hucke, R Kemper, ... Journal of medicinal chemistry 54 (20), 7005-7022, 2011 | 625 | 2011 |
| Revealing atropisomer axial chirality in drug discovery SR LaPlante, PJ Edwards, LD Fader, A Jakalian, O Hucke ChemMedChem 6 (3), 505-513, 2011 | 429 | 2011 |
| Discovery of a 1, 5-dihydrobenzo [b][1, 4] diazepine-2, 4-dione series of inhibitors of HIV-1 capsid assembly LD Fader, R Bethell, P Bonneau, M Bös, Y Bousquet, MG Cordingley, ... Bioorganic & medicinal chemistry letters 21 (1), 398-404, 2011 | 113 | 2011 |
| The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease O Hucke, MH Gelb, CLMJ Verlinde, FS Buckner Journal of medicinal chemistry 48 (17), 5415-5418, 2005 | 108 | 2005 |
| Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions A Sedykh, D Fourches, J Duan, O Hucke, M Garneau, H Zhu, P Bonneau, ... Pharmaceutical research 30, 996-1007, 2013 | 96 | 2013 |
| Resistance to a protein farnesyltransferase inhibitor in Plasmodium falciparum RT Eastman, J White, O Hucke, K Bauer, K Yokoyama, L Nallan, ... Journal of Biological Chemistry 280 (14), 13554-13559, 2005 | 89 | 2005 |
| Phosphatidylinositol 4-Kinase III Beta Is Essential for Replication of Human Rhinovirus and Its Inhibition Causes a Lethal Phenotype In Vivo C Spickler, J Lippens, MK Laberge, S Desmeules, É Bellavance, ... Antimicrobial agents and chemotherapy 57 (7), 3358-3368, 2013 | 88 | 2013 |
| Combined X-ray, NMR, and kinetic analyses reveal uncommon binding characteristics of the hepatitis C virus NS3-NS4A protease inhibitor BI 201335 CT Lemke, N Goudreau, S Zhao, O Hucke, D Thibeault, M Llinas-Brunet, ... Journal of Biological Chemistry 286 (13), 11434-11443, 2011 | 67 | 2011 |
| Sesquiterpene lactones as inhibitors of human neutrophil elastase B Siedle, S Cisielski, R Murillo, B Löser, V Castro, CA Klaas, O Hucke, ... Bioorganic & medicinal chemistry 10 (9), 2855-2861, 2002 | 61 | 2002 |
| Multiple binding sites contribute to the mechanism of mixed agonistic and positive allosteric modulators of the cannabinoid CB1 receptor N Saleh, O Hucke, G Kramer, E Schmidt, F Montel, R Lipinski, B Ferger, ... Angewandte Chemie 130 (10), 2610-2615, 2018 | 59 | 2018 |
| Discovery and structural characterization of a new inhibitor series of HIV-1 nucleocapsid function: NMR solution structure determination of a ternary complex involving a 2: 1 … N Goudreau, O Hucke, AM Faucher, C Grand-Maître, O Lepage, ... Journal of molecular biology 425 (11), 1982-1998, 2013 | 53 | 2013 |
| Structurally simple farnesyltransferase inhibitors arrest the growth of malaria parasites MP Glenn, SY Chang, O Hucke, CLMJ Verlinde, K Rivas, C Hornéy, ... Angewandte Chemie International Edition 44 (31), 4903-4906, 2005 | 53 | 2005 |
| Efficacy, Pharmacokinetics, and Metabolism of Tetrahydroquinoline Inhibitors of Plasmodium falciparum Protein Farnesyltransferase WC Van Voorhis, KL Rivas, P Bendale, L Nallan, C Hornéy, LK Barrett, ... Antimicrobial agents and chemotherapy 51 (10), 3659-3671, 2007 | 48 | 2007 |
| Enantiomeric atropisomers inhibit HCV polymerase and/or HIV matrix: characterizing hindered bond rotations and target selectivity SR LaPlante, P Forgione, C Boucher, R Coulombe, J Gillard, O Hucke, ... Journal of Medicinal Chemistry 57 (5), 1944-1951, 2014 | 41 | 2014 |
| Inhibition of HIV-1 capsid assembly: optimization of the antiviral potency by site selective modifications at N1, C2 and C16 of a 5-(5-furan-2-yl-pyrazol-1-yl)-1H-benzimidazole … M Tremblay, P Bonneau, Y Bousquet, P DeRoy, J Duan, M Duplessis, ... Bioorganic & medicinal chemistry letters 22 (24), 7512-7517, 2012 | 40 | 2012 |
| Development of Specific “Drug‐Like Property” Rules for Carboxylate‐Containing Oral Drug Candidates A Böcker, PR Bonneau, O Hucke, A Jakalian, PJ Edwards ChemMedChem 5 (12), 2102-2113, 2010 | 40 | 2010 |
| Molecular dynamics simulations and structure-based rational design lead to allosteric HCV NS5B polymerase thumb pocket 2 inhibitor with picomolar cellular replicon potency O Hucke, R Coulombe, P Bonneau, M Bertrand-Laperle, C Brochu, ... Journal of medicinal chemistry 57 (5), 1932-1943, 2014 | 37 | 2014 |
| Resistance mutations at the lipid substrate binding site of Plasmodium falciparum protein farnesyltransferase RT Eastman, J White, O Hucke, K Yokoyama, CLMJ Verlinde, MA Hast, ... Molecular and biochemical parasitology 152 (1), 66-71, 2007 | 36 | 2007 |
| Viral polymerase inhibitors T Stammers, X Barbeau, P Beaulieu, M Bertrand-laperle, C Brochu, ... US Patent App. 12/883,677, 2011 | 34 | 2011 |
| Structure-based design of novel HCV NS5B thumb pocket 2 allosteric inhibitors with submicromolar gt1 replicon potency: Discovery of a quinazolinone chemotype PL Beaulieu, R Coulombe, J Duan, G Fazal, C Godbout, O Hucke, ... Bioorganic & medicinal chemistry letters 23 (14), 4132-4140, 2013 | 28 | 2013 |
